High infiltration of CD209
dendritic cells
immunohistochemistry
macrophages
prognostic biomarkers
prostate cancer
tumor immune microenvironment
tumor infiltrating immune cells
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
13
04
2023
accepted:
09
06
2023
medline:
13
7
2023
pubmed:
12
7
2023
entrez:
12
7
2023
Statut:
epublish
Résumé
Prostate cancer (PCa) shows considerable variation in clinical outcomes between individuals with similar diseases. The initial host-tumor interaction as assessed by detailed analysis of tumor infiltrating immune cells within the primary tumor may dictate tumor evolution and late clinical outcomes. In this study, we assessed the association between clinical outcomes and dendritic cell (DC) or macrophage (MΦ) tumor infiltration as well as with expression of genes related to their functions. Infiltration and localization of immature DC, mature DC, total MΦ and M2-type MΦ was analyzed by immunohistochemistry in 99 radical prostatectomy specimens from patients with 15.5 years median clinical follow-up using antibodies against CD209, CD83, CD68 and CD163, respectively. The density of positive cells for each marker in various tumor areas was determined. In addition, expression of immune genes associated with DC and MΦ was tested in a series of 50 radical prostatectomy specimens by Taqman Low-Density Array with similarly long follow-up. Gene expression was classified as low and high after unsupervised hierarchical clustering. Numbers and ratio of positive cells and levels of gene expression were correlated with endpoints such as biochemical recurrence (BCR), need for definitive androgen deprivation therapy (ADT) or lethal PCa using Cox regression analyses and/or Kaplan-Meier curves. Positive immune cells were observed in tumor, tumor margin, and normal-like adjacent epithelium areas. CD209 A higher level of infiltration of CD209
Identifiants
pubmed: 37435060
doi: 10.3389/fimmu.2023.1205266
pmc: PMC10331466
doi:
Substances chimiques
CD163 antigen
0
Androgen Antagonists
0
Antigens, CD
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1205266Informations de copyright
Copyright © 2023 Molina, LaRue, Simonyan, Hovington, Têtu, Fradet, Lacombe, Toren, Bergeron and Fradet.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Exp Cell Res. 2019 Nov 1;384(1):111588
pubmed: 31473209
J Pathol. 2021 Oct;255(2):155-165
pubmed: 34255349
Biomed Res Int. 2014;2014:486798
pubmed: 24738060
Cytokine. 2019 Jan;113:221-227
pubmed: 30057362
Cancer Microenviron. 2013 Aug;6(2):117-22
pubmed: 23108700
J Exp Med. 2019 Oct 7;216(10):2394-2411
pubmed: 31375534
Clin Transl Med. 2022 Jan;12(1):e581
pubmed: 35075795
Oncol Ther. 2023 Mar;11(1):27-48
pubmed: 36484945
Can Urol Assoc J. 2017 Oct;11(10):298-309
pubmed: 29381452
J Cancer. 2019 Oct 15;10(24):6175-6184
pubmed: 31762828
Annu Rev Pathol. 2020 Jan 24;15:123-147
pubmed: 31530089
World J Oncol. 2019 Apr;10(2):63-89
pubmed: 31068988
Cell Death Dis. 2015 Jun 18;6:e1792
pubmed: 26086965
Breast Cancer Res. 2018 Dec 17;20(1):154
pubmed: 30558648
Oncoimmunology. 2022 Apr 15;11(1):2063225
pubmed: 35481289
Cancer Med. 2019 Sep;8(11):5202-5213
pubmed: 31355524
Science. 2006 Sep 29;313(5795):1960-4
pubmed: 17008531
J Oral Pathol Med. 2019 Oct;48(9):788-798
pubmed: 31323145
Lancet. 2018 May 26;391(10135):2128-2139
pubmed: 29754777
DNA Cell Biol. 2020 Jul;39(7):1194-1204
pubmed: 32460527
Front Immunol. 2023 Feb 09;14:1113312
pubmed: 36845095
Oral Oncol. 2022 Dec;135:106227
pubmed: 36335818
Front Immunol. 2019 Jul 12;10:1563
pubmed: 31354719
Pharmacol Ther. 2022 Nov;239:108189
pubmed: 35430292
Cancer Sci. 2019 Feb;110(2):474-480
pubmed: 30575231
Cancer. 2001 Apr 15;91(8):1414-22
pubmed: 11301387
Pathol Int. 2016 Sep;66(9):491-505
pubmed: 27444136
J Natl Cancer Inst. 2019 Mar 1;111(3):301-310
pubmed: 30321406
J Clin Pathol. 2018 Nov;71(11):1023-1027
pubmed: 30257853
Nat Commun. 2017 Sep 28;8(1):719
pubmed: 28959012
Sci Rep. 2015 Oct 27;5:15651
pubmed: 26503803
Am J Pathol. 2012 Sep;181(3):733-42
pubmed: 22796439
Nat Rev Clin Oncol. 2017 Dec;14(12):717-734
pubmed: 28741618
Int J Colorectal Dis. 2020 Jul;35(7):1203-1210
pubmed: 32303831
Histopathology. 2011 Sep;59(3):482-95
pubmed: 22034888
J Clin Oncol. 2011 Feb 20;29(6):610-8
pubmed: 21245428
Eur Urol. 2020 Jan;77(1):38-52
pubmed: 31493960
Breast Cancer Res. 2014 Nov 29;16(6):488
pubmed: 25432519
Semin Immunopathol. 2020 Oct;42(5):545-557
pubmed: 32747977
Prostate Cancer Prostatic Dis. 2012 Mar;15(1):56-62
pubmed: 21808286
Am J Cancer Res. 2013 Nov 01;3(5):523-9
pubmed: 24224130
Histol Histopathol. 2013 Dec;28(12):1621-8
pubmed: 23729368
J Clin Oncol. 2009 Dec 10;27(35):5944-51
pubmed: 19858404
Cancer Cell Int. 2020 Oct 07;20:487
pubmed: 33041668
Int J Biol Sci. 2019 Mar 10;15(5):984-998
pubmed: 31182919
Prostate. 2019 Mar;79(4):363-369
pubmed: 30500076
Immunity. 2019 Aug 20;51(2):411-412
pubmed: 31433971
Prostate Int. 2020 Jun;8(2):62-69
pubmed: 32647642
J Immunother Cancer. 2018 Dec 4;6(1):139
pubmed: 30526667
Int J Mol Sci. 2023 Apr 19;24(8):
pubmed: 37108657
Front Immunol. 2023 Apr 17;14:1166487
pubmed: 37138860
Nat Rev Immunol. 2006 Oct;6(10):715-27
pubmed: 16977338
Cancer Res. 2000 Oct 15;60(20):5857-61
pubmed: 11059783
Sci Rep. 2019 Jul 29;9(1):10961
pubmed: 31358801
Front Cell Dev Biol. 2020 Dec 17;8:613416
pubmed: 33392202
Prostate. 2019 Oct;79(14):1658-1665
pubmed: 31390096